Altimmune Inc (ALT) Stock AnalysisALTAltimmune Inc

Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Altimmune Inc is not a good buy right now due to its current price of $2.61, which is significantly below the analyst price targets of $17 and $20. The stock has a very low RSI of 13.848, indicating it is oversold, but the negative sentiment surrounding its financial performance and recent downgrades suggests further downside risk. The company has reported substantial net losses, with a net income of -22,563,000 USD for Q1 2026, which raises concerns about its financial stability. The main risk is the ongoing negative earnings trend, with a forward P/E of 8.1766, indicating that while it may be undervalued, the lack of profitability makes it a risky investment.

1 analysts cover ALT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.00.